We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-13%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$46B
AUM Growth
-$5.82B
(-11%)
Cap. Flow
+$1.91B
Cap. Flow
% of AUM
4.16%
Top 10 Holdings %
Top 10 Hldgs %
16.37%
Holding
3,033
New
111
Increased
2,420
Reduced
427
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$127M |
| 2 |
Cigna
CI
|
+$54M |
| 3 |
CVS Health
CVS
|
+$38.8M |
| 4 |
Marathon Petroleum
MPC
|
+$28.9M |
| 5 |
Diamondback Energy
FANG
|
+$19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$124M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$100M |
| 3 |
PX
Praxair Inc
PX
|
+$80.2M |
| 4 |
COL
Rockwell Collins
COL
|
+$43.7M |
| 5 |
ANDV
Andeavor
ANDV
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.95% |
| 2 | Financials | 15.85% |
| 3 | Healthcare | 14.41% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Industrials | 10.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2776
Ocular Therapeutix
OCUL
$1.87B
| $173K | ﹤0.01% |
43,465
+14,551
| +50% | +$80.2K |
|
2777
Crawford & Co Class B
CRD.B
$573M
| $172K | ﹤0.01% |
19,092
+4,620
| +32% | +$42K |
|
2778
Escalade
ESCA
$307M
| $172K | ﹤0.01% |
15,044
+4,652
| +45% | +$55K |
|
|
ARD
2779
DELISTED
Ardagh Group S.A. Class A Common Shares
ARD
| $172K | ﹤0.01% |
15,517
-66
| -0.4% | -$887 |
|
2780
Lifetime Brands
LCUT
$192M
| $170K | ﹤0.01% |
16,975
+5,104
| +43% | +$53.9K |
|
|
CMRX
2781
DELISTED
Chimerix, Inc.
CMRX
| $169K | ﹤0.01% |
65,845
+20,654
| +46% | +$69.2K |
|
|
SCTL
2782
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $169K | ﹤0.01% |
26,485
+8,562
| +48% | +$53.6K |
|
|
TNAV
2783
DELISTED
Telenav Inc.
TNAV
| $169K | ﹤0.01% |
41,745
+13,477
| +48% | +$58K |
|
2784
Kopin
KOPN
$732M
| $168K | ﹤0.01% |
167,730
+26,294
| +19% | +$47.4K |
|
2785
Northeast Bank
NBN
$1.14B
| $168K | ﹤0.01% |
+10,058
| New | +$194K |
|
|
ENZ
2786
DELISTED
Enzo Biochem, Inc.
ENZ
| $168K | ﹤0.01% |
60,542
+19,181
| +46% | +$62.8K |
|
|
AGFS
2787
DELISTED
AgroFresh Solutions Inc
AGFS
| $168K | ﹤0.01% |
44,235
+13,736
| +45% | +$68.3K |
|
|
FBM
2788
DELISTED
Foundation Building Materials, Inc. Common Stock
FBM
| $168K | ﹤0.01% |
20,189
+5,997
| +42% | +$59.5K |
|
|
NAGE
2789
Niagen Bioscience
NAGE
$234M
| $166K | ﹤0.01% |
48,511
+16,863
| +53% | +$58.6K |
|
|
PTE
2790
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $166K | ﹤0.01% |
+492
| New | +$178K |
|
2791
Amplify Energy
AMPY
$160M
| $165K | ﹤0.01% |
21,933
+6,553
| +43% | +$52.3K |
|
|
VSLR
2792
DELISTED
VIVINT SOLAR, INC.
VSLR
| $165K | ﹤0.01% |
43,243
+13,769
| +47% | +$71K |
|
2793
LiveOne
LVO
$57.2M
| $164K | ﹤0.01% |
+3,321
| New | +$129K |
|
|
BRT
2794
BRT Apartments
BRT
$267M
| $163K | ﹤0.01% |
+14,221
| New | +$163K |
|
2795
Spyre Therapeutics
SYRE
$9.2B
| $162K | ﹤0.01% |
863
+283
| +49% | +$60K |
|
|
GIFI
2796
DELISTED
Gulf Island Fabrication
GIFI
| $161K | ﹤0.01% |
22,302
+704
| +3% | +$5.93K |
|
|
CSTR
2797
DELISTED
CapStar Financial Holdings, Inc
CSTR
| $160K | ﹤0.01% |
+10,858
| New | +$167K |
|
2798
Pulse Biosciences
PLSE
$2.64B
| $159K | ﹤0.01% |
+13,917
| New | +$168K |
|
|
TLRA
2799
DELISTED
Telaria, Inc.
TLRA
| $158K | ﹤0.01% |
57,791
+19,336
| +50% | +$56K |
|
|
PMBC
2800
DELISTED
Pacific Mercantile Bancorp
PMBC
| $157K | ﹤0.01% |
22,012
+6,813
| +45% | +$54.6K |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, RhumbLine Advisers held 3,033 positions worth $46B, down 11% from $51.8B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
RhumbLine Advisers deployed $1.91B of net new capital in Q4 2018, opening 111 new positions and adding to 2,420 existing holdings. Its largest new stake was Linde: 805,738 shares worth $126M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $30.2M trimmed.
- RhumbLine Advisers's largest Q4 2018 buy was Linde: 805,738 shares worth $126M.
- RhumbLine Advisers added most to Cigna in Q4 2018, an estimated $54M increase.
- RhumbLine Advisers's biggest Q4 2018 reduction was Apple, cutting an estimated $30.2M.
- RhumbLine Advisers fully exited Aetna Inc in Q4 2018, selling an estimated $124M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $46B portfolio in Q4 2018.
- RhumbLine Advisers opened 111 new positions and closed 53 in Q4 2018.
- RhumbLine Advisers's portfolio value fell 11% quarter-over-quarter to $46B.
Based on RhumbLine Advisers's 13F filing for Q4 2018, filed 31 Jan 2019.